Lipoprotein-associated phospholipase A2, a novel cardiovascular inflammatory marker, in HIV-infected patients

Clinical Infectious Diseases

Volumn 58, Issue 6, 2014, Pages 893-900

  Mangili, Alexandra ^a   Ahmad, Raabia ^b   Wolfert, Robert L ^d   Kuvin, Jeffrey ^b   Polak, Joseph F ^c   Karas, Richard H ^b   Wanke, Christine A ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d diaDexus Inc   (United States)

Author keywords

atherosclerosis; cardiovascular; HIV; inflammation; LpPLA2

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; 1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PLA2G7 PROTEIN, HUMAN;

ADULT; AGE; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIUM SCORE; CORRELATIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; FRAMINGHAM RISK SCORE; GENDER; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; RACE; RISK FACTOR; SKINFOLD; SMOKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; CAROTID ARTERY DISEASE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MIDDLE AGED; VIROLOGY;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 84895757248     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit815     Document Type: Conference Paper

References (42)

1. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348:702-10.
2. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
3. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92:2506-12.
4. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDs 2007; 21:452-7.
5. Currier J, Taylor A, Boyd F, et al. Coronary heart disease in HIVinfected individuals. J Acquir Immune Defic Syndr 2003; 33:506-12.
6. Maggi P, Quirino T, Ricci E, et al. Cardiovascular risk assessment in antiretroviral- naive HIV patients. AIDS Patient Care STDs 2009; 23: 809-13.
7. Hsue P, Squires K, Bolger A, et al. Screening and assessment of coronary heart disease in HIV-infected patients. Circulation 2008; 118: e41-7.
8. Currier J, Lundgren J, Carr A, et al. Epidemiologic evidence for cardiovascular disease in HIV-infected patients and relationship to HAART. Circulation 2008; 118:e29-35.
9. Solages A, Vita J, Thornton D, et al. Endothelial function in HIVinfected persons. Clin Infect Dis 2006; 42:1325-32.
10. Dube M, Lipshultz S, Fichtenbaum C, et al. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Circulation 2008; 118:e36-40.
11. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83:456S-60S.
12. Tousoulis D, Antoniades C, Stefanadis C. Assessing inflammatory status in cardiovascular disease. Heart 2007; 93:1001-7.
13. Schambelan M, Wilson P, Yarasheski K, et al. Development of appropriate coronary heart disease risk prediction models in HIV-infected patients. Circulation 2008; 118:e48-53.
14. Mangili A, Polak J, Quach L, Gerrior J, Wanke C. Markers of atherosclerosis and inflammation and mortality in patients with HIV infection. Atherosclerosis 2011; 214:468-73.
15. Pearson T, Mensah G, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation 2003; 107:499-511.
16. Davidson M, Corson M, Alberts M, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 2008; 101:51F-7F.
17. Corson M, Jones P, Davidson M. Review of the evidence for the clinical utility of lipoprotein- associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101:41F-50F.
18. Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-44.
19. Madjid M, Ali M, Willerson J. Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease. Tex Heart Inst J 2010; 37:25-39.
20. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoproteinassociated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol 2006; 26:1586-93.
21. Lavi S, McConnell J, Rihal C, et al. Local production of lipoproteinassociated phospholipase A2 and lysophasphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007; 115: 2715-21.
22. Ballantyne C, Hoogeveen R, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in communities (ARIC) study. Circulation 2004; 109:837-42.
23. Mangili A, et al. Risk of cardiovascular disease in a cohort of HIV infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006; 43:1482-9.
24. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-47.
25. O'Leary DH, Polak JF, Kronmal RA, et al. Thickening of the carotid wall. A marker for atherosclerosisin the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke 1996; 27:224-31.
26. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90:18L-21L.
27. Carr JJ, Crouse JR III, Goff DC Jr, D'Agostino RB Jr, Peterson NP, Burke GL. Evaluation of subsecond gated helical CT for quantification of coronary artery calcium and comparison with electron beam CT. AJR Am J Roentgenol 2000; 174:915-21.
28. Carr JJ, Danitschek JA, Goff DC, et al. Coronary artery calcium quantification with retrospectively gated helical CT: protocols and techniques. Int J Cardiovasc Imaging 2001; 17:213-20.
29. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15:827-32.
30. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 2003; 107:499-511.
31. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008; 21: 93-111.
32. Saumoy M, Ordonex-Llanos J, et al. Low density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir. Antivir Ther 2011; 16:459-68.
33. O'Leary DH, Polak JF, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340:14-22.
34. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997; 146:483-94.
35. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34:55-63.
36. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-8.
37. Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001; 104:1863-7.
38. Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996; 27:277-84.
39. Acevedo M, Sprecher DL, Calabrese L, et al. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: "a call for cardiovascular prevention." Atherosclerosis 2002; 163:349-54.
40. Sankatsing RR, de GE, Jukema JW, et al. Surrogate markers for atherosclerotic disease. Curr Opin Lipidol 2005; 16:434-41.
41. Budoff MJ, Achenbach S, et al. Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006; 114:1761-91.
42. Stewart R, White H. The role of lipoprotein-associated phospholipase A2 as a marker and potential therapeutic targetin atherosclerosis. Curr Atheroscler Rep 2011; 13:132-37.